Biochem/physiol Actions

Reversible: no

Primary TargetcGMP-inhibited phosphodiesterase

Product does not compete with ATP.

Cell permeable: yes

Target IC₅₀: 300 pM against cGMP-inhibited phosphodiesterase

General description

Extremely potent and cell-permeable inhibitor of cGMP-inhibited phosphodiesterase (IC₅₀ = 300 pM) and platelet aggregation in vitro. Potentiates adenosine-stimulated cAMP accumulation.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Spina, D., et al. 1998. Life Sci. 62, 953.Pillai, R., et al. 1994. J. Biol. Chem.269, 30676.Tang, K.M., et al. 1994. Eur. J. Pharmacol.268, 105.Whalin, M.E., et al. 1991. Mol. Pharmacol. 39, 711.Beavo, J.A., and Reifsnyder, D.H. 1990. Trends Pharmacol. Sci.11, 150.DeClerck, F., et al. 1990. Blood Coag. Fibrinol. 1, 247.Konkle, B.A., et al. 1990. J. Biol. Chem. 265, 21867.Ruppert, D., and Weithmann, K.U. 1982. Life Sci.31, 2037.

Packaging

10 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Standard Handling (A)